Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Chetan Vakkalagadda"'
Autor:
Megan Melody, Frederique St. Pierre, Irene Helenowski, William B Pearse, Chetan Vakkalagadda, Joseph R. Leventhal, Bing Ho, John Friedewald, Daniel Ganger, Jane N. Winter, Leo I. Gordon, Adam Yuh Lin, Reem Karmali, Shuo Ma, Barbara Pro, Jonathan Moreira
Publikováno v:
Blood. 140:3833-3834
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef537fe91451b8d916f54b392b6dc3d2
https://doi.org/10.1182/blood-2022-167812
https://doi.org/10.1182/blood-2022-167812
Autor:
Chetan Vakkalagadda, Sabeeha Mukit, Masha Kocherginsky, Sheetal Mehta Kircher, Aparna Kalyan, Mary Frances Mulcahy, Al Bowen Benson, Navdeep Chandel, Devalingam Mahalingam
Publikováno v:
Journal of Clinical Oncology. 41:TPS262-TPS262
TPS262 Background: BRAF mutations drive 5-10% of colon cancers. BRAF + EGFR inhibition with encorafenib + cetuximab is standard second-line therapy, per the BEACON trial, but responses are short-lived. Autophagy induction is implicated as a mechanism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eaa926749ce6867dd35afd4a01d2848f
https://doi.org/10.1200/jco.2023.41.4_suppl.tps262
https://doi.org/10.1200/jco.2023.41.4_suppl.tps262
Publikováno v:
Journal of Clinical Oncology. 39:62-62
62 Background: The Oncology Care Model (OCM) is a Center for Medicare and Medicaid Innovation (CMMI) alternative payment model designed to enhance value in cancer care. Based on a practice’s historical performance, the model predicts a target price
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d871e792eeb69401d7fd818182f6565e
https://doi.org/10.1200/jco.2020.39.28_suppl.62
https://doi.org/10.1200/jco.2020.39.28_suppl.62
Autor:
Leo I. Gordon, Barbara Pro, William Pearse, John J. Friedewald, Daniel Ganger, Shuo Ma, Irene Helenowski, Joseph R. Leventhal, Chetan Vakkalagadda, Jane N. Winter, Reem Karmali
Publikováno v:
Blood. 136:9-10
Background Patients treated with chronic immunosuppression face a six-fold increase in their cumulative lifetime risk of lymphoma relative to age-matched immunocompetent counterparts. These malignances represent a spectrum of lymphoid and plasmacytic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0eeff0044f9c215c6ad4ba65bba7589
https://doi.org/10.1182/blood-2020-141286
https://doi.org/10.1182/blood-2020-141286
Publikováno v:
Cancers, Vol 11, Iss 3, p 421 (2019)
Cancers
Cancers
Although Hodgkin lymphoma (HL) is highly curable with first-line therapy, relapses occur in approximately 10–20% of patients with early stage disease and 30–40% of patients with advanced stage disease. The standard approach for relapsed or refrac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fe0c9e14d792abb57c1e75ac561f247
https://doi.org/10.3390/cancers11030421
https://doi.org/10.3390/cancers11030421
Publikováno v:
The American Journal of Medicine. 130:e305-e306
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d63b3121cd28854e588282ec546f033
https://doi.org/10.1016/j.amjmed.2017.02.018
https://doi.org/10.1016/j.amjmed.2017.02.018
Autor:
Suhong Luo, Bindiya Patel, Theodore S. Thomas, Kenneth R. Carson, Jesse W. Keller, Eric M. Knoche, Chetan Vakkalagadda, Kristen M. Sanfilippo
Publikováno v:
Journal of Clinical Oncology. 36:e15642-e15642
e15642Background: Locally advanced rectal cancer is commonly treated with chemoradiotherapy (CRT) followed by surgical resection. Response to preop CRT is assessed by surgical pathology findings at...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfc9f5eff668c0d112d9ca37cd2a6e09
https://doi.org/10.1200/jco.2018.36.15_suppl.e15642
https://doi.org/10.1200/jco.2018.36.15_suppl.e15642